Targeting HDACs in heart failure.

5 More presentations in this session

Novel drugs in heart failure: what's on the horizon?

Professor C. Maack (Wuerzburg, DE)

Slides Video

Effects of serelaxin on a systolic cardiac dysfunction induced by isoproterenol in mice with increased cardiac aldosterone

Doctor G. Billebeau (Paris, FR)

Abstract Slides Video

Why treatment with natriuretic peptide analogs failed to fulfill our expectations? - receptor expression and function in a failing heart.

Doctor K. Kodziszewska (Warsaw, PL)

Abstract Slides Video

ORM-3819 promotes cardiac contractility on a dual mechanism of action: troponin-C dependent calcium sensitization is supported by selective PDE III inhibition

Doctor L. Nagy (Debrecen, HU)

Abstract

Vepoloxamer (purified poloxamer-188) improves LV function, limits cardiomyocyte calcium overload and restores integrity of calciu cycling proteins in myocardium of dogs with advanced heart failure

Professor H. Sabbah (Detroit, US)

Abstract Slides Video